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Abstract
In the conducting airways of the lungs, the mobile mucus gel layer sits on top of
the airway epithelium, and through ciliary beating it is propelled up the trachea into the
pharynx where it is swallowed and cleared. This gel layer is composed of secreted
mucins that become hydrated once reaching the airway lumen. Mucins are secreted at
a baseline rate and at a stimulated rate, dependent on the amount of agonist. Baseline
secretion is responsible for steady clearance of inhaled particles and pathogens.
Stimulated secretion is thought to play a role in trapping helminths though mucus
occlusion in small airways.
Mucin exocytosis is mediated by a four helix bundle called the SNARE complex.
Prior to complex formation, three of the four helices are located on the target
membrane (t-SNARE) and one helix is vesicle bound (v-SNARE). Formation of the
complex drives fusion of the exocytic vesicle with the plasma membrane. These
SNARE interactions take place on a scaffold provided by a Munc18 protein. Prior work
in the Dickey-Tuvim laboratory has shown that different Munc18 proteins mediate
baseline and stimulated mucin secretion, indicating that different plasma membrane
exocytic machines underlie baseline and stimulated mucin secretion.
My project is to answer several questions pertaining to mucin granule biogenesis
and exocytosis, which have implications in treating diseases related to disordered
mucin production and secretion. 1) Are the polymeric mucins MUC5AC and MUC5B
packaged in the same or separate granules? 2) What components of the exocytic
machinery on mucin granules interact with the plasma membrane machines, and can
these be used as markers to define mucin trafficking prior to secretion?
iv

3) What is the nature of a mucin granule? Does it contain only newly synthesized
proteins, or does it intersect the endolysosomal system as occurs in lung alveolar
epithelial secretory cells? 4) Does the mucin granule exocytic machinery become
associated with granules in the trans-Golgi network? Does the structure of Golgi bodies
in airway secretory cells change with mucous metaplasia?
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Introduction
1. Airway mucus biology
Overview
In the lungs, mucus covers the epithelial surface of conducting airways,
providing a physical barrier against inhaled particles and pathogens. Mucins are
exceedingly large glycoproteins that form a mesh-like network within the mucus gel
layer, giving mucus its viscoelastic properties as well as its capability of trapping
inhaled particles and pathogens. Despite its protective qualities, the inability to clear
airway mucus by ciliary beating or cough is pathogenic in diseases such as asthma and
cystic fibrosis (1). In addition, the synthesis and trafficking of mucins plays a pathogenic
role in fibrotic interstitial lung diseases. Further understanding of mucin secretion is
therefore necessary to improve treatment of lung diseases.
1.1 Secretory cells
The airway is lined by a pseudostratified epithelium composed primarily of
superficial secretory cells and ciliated cells, with underlying basal cells in proximal
airways, and small numbers of scattered neuroendocrine cells, ionocytes, and tuft cells
(Fig. 1A). Secretory cells are further subcategorized based on microscopic appearance
as either club or goblet cells depending on the number of intracellular mucin granules.
A variety of products are secreted from secretory cells including the mucins MUC5AC
and MUC5B and immunomodulatory molecules such as secretoglobins (2). In large
airways, submucosal glands also contribute to the mucus gel layer. Within submucosal
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glands, serous cells secrete fluid and antimicrobial peptides such as defensins and
lysozyme while mucous cells secrete mucins (1).
1.2 Ciliated cells
Ciliated cells are the main contributors to clearance of the mucus gel layer. Each
ciliated cell has 200-300 cilia that range in length from 7 µm in proximal airways to 4
µm in distal airways (3). Ciliary beating propels the mucus from distal airways to
proximal airways and through the vocal cords where it is eventually swallowed and
cleared by the gastrointestinal tract. While ciliated cells do not secrete mucins, they do
have transmembrane mucins, glycosaminoglycans, and other glycoconjugates that
attract water with a higher osmotic pressure than mucus, resulting in the formation of a
distinct periciliary layer that is not normally penetrated by secreted mucins (4).
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Figure 1. Airway epithelium. (A) Ciliated and secretory cells line the conducting
airways. Each ciliated cell has 200-300 cilia that range in length from 7 µm in the
proximal airway to 4 µm in the distal airway. Secretory cells contain large yellow
mucin granules that can reach up to 1 µm in diameter and small black granules
which contain proteins. (B) Electron micrograph of a Muc5b polymer partially
expanded after secretion. The white arrow indicates a globular node where
monomers appear to be connected. A polymer can have up to 20 monomers
connected in an end-to-end fashion. (C) Electron micrograph of an extended Muc5b
polymer showing a monomer approximately 500 nm in length. Reproduced with
permission from The New England Journal of Medicine, Copyright Massachusetts
Medical Society. Fahy, J. V., and B. F. Dickey. 2010. Airway mucus function and
dysfunction. N Engl J Med 363: 2233-2247.

1.3 Mucus composition
Normal airway mucus is composed of approximately 98% water and 2% solids.
Of the solids, mucins account for one-third with salts and non-mucin proteins the
remainder. Mucins are 50-90% carbohydrate and can absorb several hundred times
their weight in water (1). The degree of hydration significantly affects the viscoelastic
and adhesive-lubricant properties of mucus, resulting in dramatic differences in the
ease with which it is cleared by ciliated cells.
The mucus gel layer sits on top of the denser periciliary layer, which normally
prevents secreted mucins from touching the epithelial cell surface in the gel-on-brush
model (4). Within the periciliary layer, airway epithelial cells release adenosine
3

triphosphate (ATP) in response to mechanical stress. Extracellular ATP reaches a
concentration that is sufficient activate P2Y2 purinergic receptors on secretory cells,
tonically inducing secretion at a low baseline rate. When the rate of ATP release is
increased due to inflammatory or mechanical stimuli, or other inflammatory mediators
such as histamine are released, intense phasic (stimulated) mucin secretion occurs (5,
6).
2. Mucin structural organization
2.1 Mucin glycoproteins
There are seven mucins expressed in the lungs, of which four are
transmembrane mucins and three are secreted. Muc1 is found on the apical surface of
airway epithelial cells, localizing predominantly on microvilli. Muc4 and Muc20 are
found on ciliated cells, localizing to cilia (7). Muc16 is the largest mucin produced in the
airway containing both a transmembrane domain and a proteolytic cleavage site where
it can be cut to become part of the mobile gel layer (8).
Muc5ac, Muc5b, and Muc7 are secreted, but Muc7 does not polymerize to form
a gel. Muc5ac and Muc5b are the predominant gel-forming mucins in the airway (9).
Muc5ac is produced in proximal human airways and far less in distal airways under
non-metaplastic conditions. Muc5b is expressed throughout the conducting airway and
in submucosal glands (10). Mouse airways are akin to human distal airways of
comparable diameter, with Muc5b being the predominant secreted mucin in nonmetaplastic conditions.
2.2 Structures of MUC5AC and MUC5B
4

Mucins are large macromolecules with the apoprotein ranging from 3000-5000
amino acids in sequence. Muc5ac and Muc5b monomers are approximately 500 nm in
length, and can form homotypic polymers comprised of up to twenty monomers (Fig.
1B-C) (1). Mucin monomers homodimerize C-terminal-to-C-terminal in the endoplasmic
reticulum (ER) and the homodimers polymerize N-terminal-to-N-terminal with further Cterminal polymerization in the Golgi body.
Muc5ac and Muc5b monomers contain von Willebrand factor D (vWD)-like
domains terminally with cysteine-rich domains (CysD) and proline, threonine, serine
(PTS) rich sequence centrally (Fig 2A). Polymerization occurs at the vWD-like terminal
domains, which have cysteine-rich regions that allow disulfide bonds to form. PTS
tandem repeats are sites of O-glycosylation and are present in all mucins. The number
of repeats and specific sequences are variable between mucin types, thus affecting
glycosylation patterns and physical properties. CysD domains are interspersed among
PTS domains and are thought to confer flexibility and provide additional sites for
mannosylation. Mannosylation has a role in intracellular trafficking, protein folding, and
localization, and is thought to be essential for Muc5ac and Muc5b maturation from the
ER (9).
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Figure 2. Muc5ac and Muc5b monomers. (A) Muc5ac and Muc5b monomers
contain von Willibrand factor D (vWD)-like domains terminally with cysteine-rich
domains (CysD) and proline, threonine, serine (PTS) rich sequence centrally. (B)
Four core glycosylation types. β1-3 linkage of galactose to N-acetylgalactosamine
(GalNAc) to form core 1. Additional β1-6 linkage of N-acetylglucosamine (GlcNAc) to
core 1 to form core 2. β1-3 linkage of GlcNAc to GalNAc to form core 3. Additional
β1-6 linkage of GlcNAc to core 3 to form core 4. Elongation with different sugars to
form glycans that can branch further depending on the core type. Reprinted with
permission from the Biochemical Society Transactions. Symmes, B. A., A. L.
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Stefanski, C. M. Magin, and C. M. Evans. 2018. Role of mucins in lung homeostasis:
regulated expression and biosynthesis in health and disease. Biochem Soc Trans 46:
707-719.

2.3 Mucin glycosylation
During the initiation phase of O-glycosylation in the Golgi, Nacetylgalactosamine (GalNAc)-transferase adds a GalNAc to the hydroxyl side of a
serine or threonine in PTS domains. Afterward, neutral sugars, galactose (Gal) or
GalNAc are added to create four different core types that are elongated with different
sugars to form glycans that can branch further depending on the core type (Fig 2B).
Glycosylated structures can terminate in Gal or GalNAc (uncapped) or with sialic acid
or sulfate (capped). Glycans can also be further modified with the addition of fucose.
The extent of glycosylation that a mucin monomer undergoes is enough to increase its
mass 3-5 fold (9).
3. Mucin production and function
3.1 Muc5ac
Very little Muc5ac is present in mouse airways and human distal airways under
non-metaplastic conditions (10-12). However, during allergic inflammation Muc5ac
production can increase 40-fold while Muc5b only increases 3-10 fold (1). This drastic
increase in Muc5ac during inflammation has made it a detrimental factor in mucoobstructive diseases such as asthma, cystic fibrosis (CF), and chronic obstructive
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pulmonary disease (COPD). The regulation of Muc5ac is therefore of interest due to its
pathological implications.
Epidermal growth factor receptor (EGFR) signaling has been shown to induce
Muc5ac expression while Foxa2 represses it (13, 14). Besides EGFR signaling, type 2
inflammatory cytokines such as interleukin (IL)-13 also induce Muc5ac expression
through binding of hypoxia-inducible factor (HIF)-1 to the promoter region and
upregulation of SAM pointed domain-containing ETS transcription factor (SPDEF) to
inhibit Foxa2 mediated repression (9, 15, 16).
Under normal conditions, Muc5ac knockout (KO) mice have normal mucociliary
clearance. In an allergic asthma model, Muc5ac KO mice are protected with less
severe mucus occlusion compared to wild type (WT) mice (12). However, Muc5ac KO
mice are susceptible to chronic worm infections, and Muc5ac is required for clearance
of helminths from the cecum (17). Muc5ac also plays a vital role in trapping parasites in
the lungs (18)
3.2 Muc5b
Muc5b is the predominant gel-forming mucin produced in mice responsible for
clearance of inhaled particles and microbes. While transcriptional mechanisms are not
yet well understood, transcription factor NK2 homebox 2-1 (NKX2-1) also known as
thyroid transcription factor-1 (TTF-1) represses Muc5b gene expression while GATA-6
activates it (19).
In Muc5b KO mice, there is an increase in mortality due to the inability to clear
conducting airways of particles and pathogens. Even with functional cilia, Muc5b KO
8

mice had chronic bacterial infections and accumulation of materials such as hair is
found in the posterior nasopharynxes and trachea (20). A study of Muc5b heterozygous
KO mice found that there was approximately 50% reduction in mucociliary clearance
compared to WT, indicating that Muc5b is limiting for mucociliary clearance (21).
4. Mucin secretion
4.1 Constitutive and regulated secretion
All cells have a constitutive secretory pathway in which lipids and proteins
undergo continuous exocytosis from post-vesicles to maintain plasma membrane
integrity, regardless of external stimuli. Some specialized cells have a regulated
secretory pathway in which granules are secreted in response to external stimuli. Mucin
secretion is ligand dependent, making it a regulated process (22).
4.2 Baseline secretion
Mucin production and mucin secretion are two separate processes. In
uninflamed conditions, the rates of mucin production and secretion closely match, and
very little mucin accumulation is visible in histochemical stains (Fig. 3, left column).
With exposure to an allergen such as ovalbumin (OVA), mucin production increases in
response to IL-13, and accumulation of mucin granules become apparent (Fig. 3,
middle column).
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Figure 3. Mucin secretion in proximal and distal airways. Top row shows formalin
fixed, Alciab blue and periodic acid-Schiff (AB/PAS) staining of mouse proximal
airway with intracellular mucin stained purple. Bottom row shows methacarn fixed,
periodic acid fluorescent-Schiff (PAFS) staining of mouse distal airways with mucin
stained red. Left column shows uninflamed airway with little mucin accumulation.
Middle column shows mucin hyperproduction (mucous metaplasia) with addition of
ovalbumin (OVA). Right column shows stimulated secretion with addition of excess
ATP. Scale bar is 10 µm in the top row and 50 µm in the bottom row. Reprinted with
permission of the American Thoracic Society. Copyright © 2020 American Thoracic
Society. All rights reserved. Annals of the American Thoracic Society is an official
journal of the American Thoracic Society. Jaramillo, A. M., Z. Azzegagh, M. J. Tuvim,
and B. F. Dickey. 2018. Airway Mucin Secretion. Ann Am Thorac Soc 15: S164S170.
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4.3 Stimulated secretion
The rate of mucin secretion can be stimulated with the addition of excess ATP,
as seen in the mouse airway (Fig. 3, right column, top row). The rapid release and
hydration of accumulated intracellular mucin results in mucus occlusion of small
airways (Fig. 3, right column, bottom row). Degranulation events in goblet cells have
been studied by high speed videomicroscopy following the addition of ATP. Stimulated
secretion had a 1,760-fold increased rate over baseline, with similar findings between
normal and CF human airway (22-24).
4.4 Exocytosis
The central molecular mediators of exocytosis are soluble N-ethylmaleimidesensitive factor attachment protein receptors (SNAREs). However, before SNAREs
drive fusion of a vesicle with the plasma membrane, certain steps need to occur. These
include tethering, docking, priming, and fusion. It has been established that Rabs
participate in each of these steps.
Rab proteins are a part of the Ras-like GTPase super family. Over 60 Rabs are
expressed in humans, and many studies have localized Rab proteins to distinct
intracellular compartments with roles in transport between organelles. For each step of
exocytosis, Rabs interact with proteins that act as effectors to transduce signaling.
Multiple different Rabs can be on a vesicle and an exchange of Rabs occur at different
stages of exocytosis.
Notable Rabs in secretion include Rab8 which participates in trafficking from the
trans-Golgi network (TGN) to the plasma membrane for the constitutive secretory
11

pathway, and Rab3 which participates in regulated secretion (25). The isoform Rab3d
has been reported by the Dickey/Tuvim Laboratory to be restricted to airway secretory
cells expressing club cell secretory protein (CCSP) (11, 26).
In exocytosis, tethering refers to linking the vesicle with the target membrane,
bringing the membranes close together in preparation for fusion. There appears to be
two general class of tethering factors - large coiled-coil proteins, and multi-subunit
tethering complexes that include four to eight related proteins.
A large number of coiled-coiled proteins have been found associated to Golgi
membrane called “golgins”. Golgi matrix (GM) 130, also known as golgin-95, is found
to associate with Golgi reassembly-stacking protein (GRASP) 65, which is a found on
the cis-Golgi. The GM130:GRASP65 complex is a Rab1 effector. Binding to Rab1-GTP
is required for ER coat protein (COP) II vesicle fusion to the cis-Golgi (27).
Docking is generally understood as the stage in which vesicles are at a minimal
distance from the target membrane prior to fusion. Although mechanistically not fully
understood, Sec1/Munc18 (SM) proteins have been implicated (28). Mouse chromaffin
cells deficient in Munc18a, also known as Munc18-1, have a docking defect in which
calcium-dependent large dense core vesicle exocytosis was reduced 10-fold. In
contrast, bovine chromaffin cells overexpressing Munc18a had an increase in fusioncompetent vesicles (29).
Priming prepares vesicle for fusion. In the case of SNARE mediated vesicle
fusion, complexins have been found to bind the SNARE complex, inhibiting fusion.
Calcium bound synaptotagmin (Syt) interaction then releases this inhibition, thus
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priming the SNARE complex (30). Finally, fully coiled SNARE proteins provide the
energy necessary for membrane fusion.
5. Mucin exocytic machinery
5.1 SNAREs
SNARE proteins are required for all intracellular trafficking of vesicles on the
endocytic and exocytic pathways. Each SNARE protein has a SNARE motif that is
approximately 70 residue in length. This SNARE motif is capable of assembly with
three other SNAREs to form a four helix complex in parallel (30). There are four groups
of SNAREs - Qa, Qb, Qc, and R-SNARE (31). R-SNAREs have an arginine at the
midpoint of the conserved zero ionic layer, and Q-SNAREs have glutamine at that
place. Polar interactions at the center of the hydrophobic SNARE assure correct
alignment of the SNARE complex.
SNAREs are also classified as v-SNARE and t-SNARE, with R-SNAREs
associated to the vesicle (v)-SNAREs and Q-SNAREs to the target membrane (t)SNAREs (32). In exocytosis, a t-SNARE synaptosomal-associated protein (SNAP)
contributes two helices and a Syntaxin contributes one helix to the SNARE complex.
The vesicle associated membrane protein (VAMP), located on the vesicle, contributes
the fourth helix to the SNARE complex (Fig. 4) (22).
VAMPs are unique in that they are the only SNARE located on the vesicle. Many
studies of vesicle trafficking have been done in neurons with a synaptic vesicle as a
model. The most abundant protein decorating a synaptic vesicle is VAMP2, with
approximately 70 copies per vesicle (33). This makes VAMPs an attractive granule
13

marker in the process of understanding mucin secretion. In Calu-3 cells, a lung
epithelial cell line, VAMP8 is the most abundantly expressed VAMP, with VAMP3
coming in second (34). Knowing that baseline and stimulated secretion are present, it is
likely that different VAMPs mediate each exocytic machinery. Potentially, even Muc5ac
and Muc5b may be segregated with Muc5b secretion favoring the baseline secretory
machinery and Muc5ac favoring the stimulated secretory machinery, based upon the
roles of Muc5ac in trapping migrating helminths and Muc5b providing baseline
mucociliary clearance.
Specific SNAREs in the airway include SNAP23, which participates in both
baseline and stimulated mucin secretion as shown by the Dickey/Tuvim Laboratory
(35). SNAP23 contains two t-SNARE helices connected by a linker region that contains
palmitoyl groups, allowing it to be anchored to the membrane. In unpublished work, the
Dickey/Tuvim laboratory has found that Syntaxin-3 participates in stimulated mucin
secretion, but Syntaxin function in baseline mucin secretion has not yet been studied.
VAMP8 has been found to mediate stimulated airway mucin secretion, and to be
localized to MUC5AC-containing granules (34). The details of my investigations of
VAMP proteins mediating baseline mucin secretion are described later in the thesis
text. However in brief, I found that both VAMP8 KO and VAMP3 KO mice had a
baseline secretion defect.
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Figure 4. A generic model of mucin exocytosis. The left depicts specific proteins
participating in airway mucin exocytosis. The four helices that make up the SNARE
complex is represented by black bars, including synaptosomal-associated protein
(SNAP), syntaxin (Stx), and vesicle associated membrane protein (VAMP). The SM
protein, mammalian uncoordinated (Munc)-18, is shown interacting with Stx at the
plasma membrane along with the regulatory protein Munc13. The right shows a
simplified signaling pathway of mucin exocytosis over a time course. An agonist
binds a heptahelical receptor at the plasma membrane, activating trimeric G protein
(Gq) then phospholipase-Cβ (PLC), generating secondary messengers diacylglycerol
(DAG) and inositol triphosphate (IP3). DAG binds Munc-13, allowing Stx to be in an
open conformation at the plasma membrane. IP3 induces calcium release from the
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endoplasmic reticulum (ER). Free calcium activates synaptotagmin (Syt) which
promotes further coiling of the SNARE complex enabling fusion and release of mucin
into the extracellular space. Munc18 provides acts as a scaffold, bringing the
SNAREs together prior assembly. Reprinted with permission of the American
Thoracic Society. Copyright © 2020 American Thoracic Society. All rights reserved.
Annals of the American Thoracic Society is an official journal of the American
Thoracic Society. Jaramillo, A. M., Z. Azzegagh, M. J. Tuvim, and B. F. Dickey. 2018.
Airway Mucin Secretion. Ann Am Thorac Soc 15: S164-S170.

5.2 SM proteins
SM proteins provide a physical platform that is critical for proper SNARE
assembly. Seven isoforms are present within mammals, and of the seven, Munc18a,
Munc18b, and Munc18c have been found to play roles in secretion (36). Munc18a,
Munc18b, and Munc18c KO mice were all nonviable after birth. Thus, Munc18
conditional deletant mice were generated in the Dickey/Tuvim Laboratory, in which the
deletion was only in airway epithelial cells. It was discovered that Munc18a deletant
mice spontaneously accumulated mucin, signifying a baseline secretion defect. With
addition of excess ATP, Munc18a deletant mice were able to secrete just like WT mice,
indicating that the stimulated secretory pathway was unaffected by the absence of
Munc18a. In contrast, Munc18b deletant mice also showed a modest amount of
spontaneous mucin accumulation, but there was a severe defect in stimulated
secretion. Munc18c deletant mice had no observed secretory defect (36). These
findings identified the presence of two separate exocytic machineries acting at the
16

plasma membrane in airway mucin secretion. These are defined by the role of
Munc18a in baseline mucin secretion, and Munc18b in stimulated mucin secretion.
Presumably, Munc18c acts in basolateral secretion, as it does in other polarized cell
types.
5.3 Regulatory proteins
As mentioned previously, Synaptotagmins (Syt)s plays a crucial role in priming.
There are seventeen Syt isoforms, but not all are calcium sensitive. Syt2 was found by
the Dickey/Tuvim laboratory to be the calcium sensor in stimulated mucin secretion
(26). Besides Syt2, other regulatory proteins involved in priming include Munc13.
Munc13 is thought to act in concert with Munc18 to opens up Syntaxin (30). Munc13
has 5 isoforms, and only Munc13-2 and Munc13-4 are found in the airway. Munc13-2
KO mice had a baseline mucin secretion defect and a partial stimulated secretion
defect as found by the Dickey/Tuvim laboratory in collaboration with the Davis
laboratory (37). Mice with that were deficient in both13-2 and 13-4 had a greater
stimulated secretion defect (unpublished data, Dickey/Tuvim Laboratory).
Mucus dysfunction in lung disease
6. Allergic Asthma
6.1 Cell biology of allergic asthma
Over 300 million people worldwide have asthma, making it the most common
chronic inflammatory lung disease. It is more prevalent in developed countries and
more common in urban areas. Many factors play a role in the development of asthma
including age, sex, and environment. Three characteristics of asthma are increased
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eosinophils in the lungs, airway smooth muscle hyper-responsiveness to contractile
stimuli, and mucous metaplasia in airway epithelium. There are many subsets of
asthma but here we will focus on allergic asthma.
Allergic asthma is a Type 2 inflammatory disease that is sustained by TH2 cells.
During allergen sensitization, airway epithelial cells through TLR stimulation activate
the MyD88 pathway which induces the production of IL-25, IL-33, and TSLP. These
cytokines then activate dendritic cells (DCs), mast cells, basophils, and type 2 innate
lymphoid cells (ILC2s). ILC2s then produce IL-5, IL-9, and IL-13 as a response.
DCs sample inhaled particles in the lumen. After activation, DCs migrate to
lymph nodes to present the antigen to naïve T cells, driving T cell differentiation into
TH2 cells. TH2 cells then secrete pro-allergic cytokines IL-3, IL-4, IL-5, IL-9, IL13, and
granulocyte-macrophage colony-stimulating factor (GM-CSF). Of the cytokines
involved, IL-4, IL-9, IL-13 are sufficient in causing mucous metaplasia (38).
6.2 The role of mucus in asthma
Mucus plugging of the airway is commonly seen in patients with fatal asthma (1).
As previously mentioned, IL-13 contributes to the sudden upregulation of mucin
production, particularly Muc5ac. In humans, an increase of Muc5ac and decrease of
Muc5b is specific to TH2 type asthma (39). The change in mucin ratio affects mucous
physical properties, which makes clearance more difficult. In the case of asthma,
mucus obstruction, inflammation, and airway smooth muscle contraction make a deadly
combination.
6.3 Therapeutics
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Inhaled corticosteroids combined with β-adrenergic agonists are the most
important current treatments for asthma. β-adrenergic agonists are bronchodilators that
relax the smooth muscle airway, providing a quick relief from airflow obstruction.
Inhaled corticosteroids have an anti-inflammatory effect, reducing leukocytes in the
mucosa and submucosa, goblet cell metaplasia, and angiogenesis (40). Monoclonal
antibodies directed against IgE, IL-5,or IL-4R-alpha are newer agents directed at
reducing inflammation in severe chronic asthma (41)
For mucus-specific treatments, inhaled hypertonic saline is used to hydrate the
airway. This reduces mucous viscoelasticity and promotes mucociliary clearance (42).
N-acetylcysteine breaks disulfide bonds in mucin polymers and is effective in
solubilizing sputum ex vivo, however due to the fact that it is an irritant in the airway
with very low potency in breaking disulfide bond, it is not routinely used for mucus
clearance in vivo (1). Newer reducing agents with greater potency and less toxicity are
in development (43).
Another potential area of drug therapy may be in targeting exocytic machinery
components. In an IL-13 induced allergic asthma model, Munc18b deletant mice were
protected compared to their WT counterparts with a 62% decrease in luminal mucus.
This is an attractive concept since deletion of Munc18b does not affect baseline
secretion needed for mucociliary clearance (36).
7. Cystic fibrosis
7.1 Cell biology of CF
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Cystic fibrosis (CF) is the most common life-limiting genetically inherited disease
in Caucasians, affecting over 70,000 people worldwide and 1 out of every 2,500-4,000
newborns in North America and Europe (44). CF is cause by mutations in the cystic
fibrosis transmembrane conductance regulator (CFTR) gene. CFTR is an integral
transmembrane protein that transports chloride and bicarbonate anions across apical
epithelial cell surfaces in the lungs, sinuses, gastrointestinal tract, sweat glands, and
elsewhere. Dysfunction in CFTR results in abnormally viscous mucus, chronic bacterial
infection, and inflammation, which is particularly devastating in lungs and the primary
cause of morbidity and mortality.
There are five classes of CF mutations: Class I where no CFTR protein is
created; Class II where CFTR is misfolded and does not reach the cell surface; Class
III where the protein reaches the cell surface but has a gating problem; Class IV where
CFTR is at the cell surface but the ion channel is faulty; and class V where there is an
insufficient amount of CFTR created (45).
Due to the decrease in anion secretion by CFTR, insufficient sodium is present
in the airway lumen. Salt concentration increases intracellularly, drawing in water, and
dehydrating the periciliary and mucus gel layers. This causes mucus adhesion to the
airway epithelial cell surface, affecting mucociliary clearance (46).
The sputum from CF patients was found to contain IL-1β, IL-1α, TNF-α , IL17A/F, neutrophil elastase, and the neutrophil chemoattractant, IL-8. The cytokine IL1β increases both Muc5ac and Muc5b production, with Muc5b being more prominent.
CF is also characterized by neutrophilic inflammation in the absence of infection,
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thought to be due to epithelial hypoxia and apoptosis due to adherent mucus plaques
(47).
7.2 The role of mucus in CF
In healthy lungs, mucus aids in clearance of inhaled pathogens in the airway. In
CF lungs, mucus becomes concentrated due to mucin overproduction and dehydration
from salt imbalances. This leads to a mucociliary clearance defect, chronic bacterial
infection, and mucus plug formation (48).
7.3 Therapeutics
CF drugs are divided into potentiators and correctors. Ivacaftor is a potentiator
targeting class III mutations by improving ion movement through the channels. During
Phase III clinical trials, 75% of the subjects taking ivacaftor for 24 weeks had a 5% or
more increase in forced expiratory volume in 1 second (FEV1), a readout for lung
function (44). Tezacaftor was developed as a corrector for the CFTR protein, targeting
class II mutations. Combination therapy of ivacaftor and tezacaftor has been approved
in 2018 (45).
For the treatment of pathogenic mucus, inhaled hypertonic saline was shown to
improve mucus clearance and lung function in CF patients. Mucus clearance rate was
sustained for more than 8 hours, suggesting that hydration of the airway led to
improved mucus clearance (49).
Targeting mucin secretion may have therapeutic benefits for CF. In a mouse
model mimicking CF, Munc18b deletion decreased mucous occlusion by 66% as
demonstrated by the Kreda laboratory in collaboration with the Dickey/Tuvim
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laboratory. Neutrophilic inflammation was still present in mice, therefore potential drugs
targeting exocytic proteins may work best in combination with other CF drugs (36).
8. Chronic obstructive pulmonary fibrosis
Chronic obstructive pulmonary disease (COPD) is characterized as persistent
airflow limitation due to either genetic or environmental factors or both. Approximately
2.7 million deaths worldwide are attributed to COPD each year (50). This section
focuses primarily on COPD associated with long-term cigarette smoking. Cigarette
smoking is a major environmental factor in developing COPD and is associated with
increased mucin concentration (51). Although not all smokers develop COPD, the long
term repeated process of inhaling particulates from cigarettes is sufficient for inducing
lung injury. Toxic gases also enter the lungs, inducing oxidative stress and
inflammatory responses. Among these gases, acrolein in particular has been shown to
induce mucous metaplasia (52). The infiltration of neutrophils, macrophages, and
lymphocytes is associated with disease severity. Features of COPD include fibrotic
thickening of airway walls, damage in the alveolar region termed emphysema, and
mucus hyper secretion (53). Compared to people who have never smoked, current or
former smokers with COPD have 3 times as high Muc5b and 10 times as high Muc5ac,
with Muc5b being the predominant mucin found in sputum (54).
9. Idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive lung disease in
which scarring of the alveolar region occurs. IPF affects approximately 3 million people
worldwide, with incidence increasing with age. Repetitive lung injury could lead to a
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maladaptive response in genetically susceptible individuals. Risk factors associated
with IPF include smoking, chronic viral infections, and genetics. Although fibrosis
primarily occurs in the alveolar region, a risk factor in developing IPF is the gain-offunction mutation of MUC5B (55).
In humans, a polymorphism that causes overexpression of MUC5B was found to
be a risk factor for IPF (56). Surprisingly, even though 20% of Caucasians have the
polymorphism, IPF remains a rare disease. This could be speculated that the mutation
is selected for despite the associated risk of developing interstitial lung disease, likely
to due proteostasis stress. A reason for the selection could be due to enhanced
protection of the airway epithelium from inhaled pathogens. This may be comparable to
how people with the allele for sickle hemoglobin are protected against malaria (57).
MUC5B is found in distal airways and in honeycomb cysts that form in human IPF
lungs. In mice, overexpression of Muc5b is associated with fibrogenesis following lung
injury. However, with treatment of a mucolytic agent there is a decrease of collagen
deposition in Muc5b overexpressing mice (58).
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Results
Overview
As described in the Introduction section, secretion of the polymeric gel-forming
mucins MUC5AC and MUC5B into the airway lumen is an essential defense against
particles and pathogens. However, under some circumstances this process causes
pathophysiology. Prior work in our laboratory found that there are two distinct molecular
exocytic machines at the plasma membrane that mediate baseline and stimulated
mucin secretion. My work addresses several questions that arise from this prior work:
1) Are the polymeric mucins MUC5AC and MUC5B packaged in the same or
separate granules. If separate, are they secreted exclusively by only one of
the exocytic machines?
2) What components of the exocytic machinery on mucin granules interact with
the plasma membrane machines, and can these be used as markers to
define mucin trafficking prior to secretion?
3) What is the nature of a mucin granule? Does it contain only newly
synthesized proteins, or does it intersect the endolysosomal system as
occurs in lung alveolar epithelial secretory cells?
4) Does the mucin granule exocytic machinery become associated with
granules in the trans-Golgi network? Does the structure of Golgi bodies in
airway secretory cells change with mucous metaplasia?
Answering these questions is vital to understanding mucin granule biogenesis
and exocytosis, which has implications for understanding and treating diseases of
disordered mucin production and secretion.
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10. Muc5ac and Muc5b are stored in the same and separate granules
10.1 Colocalization of Muc5ac and Muc5b in mouse airways
To address mucin packaging within granules, we examined mice stimulated with
either IL-13 or IL-1β to upregulate Muc5ac production (mucous metaplasia) since very
little Muc5ac is produced under non-inflammatory conditions. The cytokine IL-13 is a
cytokine implicated in asthma and IL-1β is implicated in CF and COPD. We used both
cytokines to generalize our findings and different doses were administered to determine
optimal levels sufficient for Muc5ac expression and visualization but not excessive
expression to allow adequate resolution of granules.
Colocalization analysis is generally done to determine the physical association
of different proteins. Two commonly used methods to determine colocalization are
measurement of Pearson’s correlation coefficient (PCC) and Mander’s colocalization
coefficients (MCC). PCC examines the relationship between two proteins on a scale of
-1 to +1, representing negative correlation and positive correlation in which zero is no
correlation. MCC has two values, M1 and M2, which quantify the degree of cooccurrence of two proteins. MCC values are based on a scale of 0 to +1, representing
non-overlapping and complete overlapping of pixels, respectively (59).
In IL-13 induced metaplasia, we observed airway secretory cells that expressed
both Muc5ac (red) and Muc5b (green). A line-scan analysis was performed across the
longest length of the cell (Fig 5.A), and the plot generated shows areas of no
colocalization (white triangles) and colocalization (black triangle) of Muc5ac and Muc5b
(Fig. 5.B). Only cells that produced both mucins were selected for colocalization
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analysis and generation of PCC and MCC values. The PCC values of 40 cells were
plotted with a median value of 0.65, signifying a moderate positive correlation of
Muc5ac and Muc5b in IL-13-treated mouse airways (Fig. 5C). The same cells were
used to generate MCC values, and the median value for M1 was 0.57 and for M2 was
0.70 (Fig. 5D). M1 indicates the fraction of green pixels (Muc5b+) that overlap red
pixels (Muc5ac+), and M2 indicates the fraction of red (Muc5ac+) pixels that overlap
green pixels (Muc5b+). This analysis showed that a higher fraction of Muc5ac is
colocalized with Muc5b and that more Muc5b granules do not contain Muc5ac. Some
granules containing only Muc5b can be seen at the apical surface of the secretory cell
in an IL-13 treated mouse airway (Fig. 5A), and such granules were frequently
observed.
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Figure 5. Colocalization of Muc5ac and Muc5b in mouse airways. (A)
Representative image of a mouse airway treated with IL-13 and stained with Muc5ac
(red) and Muc5b (green). (B) Line-scan analysis corresponding to arrow drawn in (A)
showing no colocalization (white triangle) and colocalization (black triangle). (C)
Pearson’s correlation coefficient for Muc5ac and Muc5b in airways treated with IL-13.
Box shows median and interquartile range and whiskers show 10th and 90th
percentiles. N = 40 cells from 4 mice. PCC = 0.65. (D) Mander’s colocalization
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coefficients for mouse airways treated with IL-13. M1 indicates the fraction of green
pixels (Muc5b+) that overlap red pixels (Muc5ac+), and M2 indicates the fraction of
red (Muc5ac+) pixels that overlap green pixels (Muc5b+). N = 40 cells from 4 mice.
M1 = 0.57 and M2 = 0.70. (E) Representative image of a mouse airway treated with
IL-1β and stained with Muc5ac (red) and Muc5b (green). (F) Line-scan analysis
corresponding to arrow drawn in (E). (G) Pearson’s correlation coefficient for Muc5ac
and Muc5b in airways treated with IL-1β. N = 17 cells from 4 mice. PCC = 0.75. (H)
Mander’s colocalization coefficients for mouse airways treated with IL-1β. M1 = 0.68
and M2 = 0.74. Scale bar is 5 µm.

The same analysis was conducted using IL-1β to induce mucous metaplasia
(Fig. 5E-H). PCC values of 17 cells were plotted with a median value of 0.75, signifying
a positive correlation between Muc5ac and Muc5b in IL-1β treated mouse airways (Fig.
5G). The same cells were used to generate MCC values, and the median value for M1
was 0.68 and M2 was 0.74 (Fig. 5H). Mucins produced under IL-1β treatment are more
colocalized than mucins produced under IL-13 treatment.
10.2 Colocalization of MUC5AC and MUC5B in human airways
Colocalization analysis of MUC5AC and MUC5B was also done on human
proximal airways and distal human airways. In human airways, mucin production is also
varied, as in mice. Analysis of a proximal human airway revealed a MUC5B-only cell
adjacent to a MUC5AC and MUC5B containing cell (Fig. 6A). The median PCC value
for human proximal airways was 0.57 (Fig. 6C), and the median value for M1 is 0.63
and M2 is 0.66.
28

In distal human airway cells (Fig. 6E-H), the median PCC value was 0.64 while
M1 was 0.48 and M2 was 0.76. A higher proportion of MUC5AC in distal human airway
is colocalized with MUC5B than MUC5B colocalized with MUC5AC.

Figure 6. Colocalization of MUC5AC and MUC5B in human airways. (A)
Representative image of a proximal human airway stained with Muc5ac (red) and
Muc5b (green). (B) Line-scan analysis corresponding to arrow drawn in (A) showing
no colocalization (white triangle) and colocalization (black triangle). (C) Pearson’s
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correlation coefficient for Muc5ac and Muc5b in proximal human airway. Box shows
median and interquartile range and whiskers show 10th and 90th percentiles. N = 9
cells. PCC = 0.57. (D) Mander’s colocalization coefficients for proximal human
airway. M1 indicates the fraction of green pixels (Muc5b+) that overlap red pixels
(Muc5ac+), and M2 indicates the fraction of red (Muc5ac+) pixels that overlap green
pixels (Muc5b+). N = 9 cells from 1 subject. M1 = 0.63 and M2 = 0.66. (E)
Representative image of a distal human airway stained with Muc5ac (red) and Muc5b
(green). (F) Line-scan analysis corresponding to arrow drawn in (E). (G) Pearson’s
correlation coefficient for Muc5ac and Muc5b in distal human airway. N = 11 cells
from 1 subject. PCC = 0.64. (H) Mander’s colocalization coefficients for distal human
airway. M1 = 0.48 and M2 = 0.76. Scale bar is 5 µm.

11. VAMP3 and VAMP8 together mediate mucin granule exocytosis
11.1 Both VAMP3 and VAMP8 participate in baseline mucin secretion
As described in the Introduction, the v-SNARE present on trafficking vesicles is
usually a member of the VAMP family. A previous study reported that VAMP8 regulates
mucin secretion in airway goblet cells (34). With deletion of VAMP8, there was a severe
defect in stimulated secretion, but the degree of a possible defect in baseline secretion
was not measured. We decided to pursue the possibility that there is another VAMP
isoform that mediates baseline secretion only, possibly mirroring how Munc18a
selectively mediates baseline secretion (36). In the human epithelial lung cell line, Calu3, it was found that VAMP8 RNA transcripts were the most abundant, followed by
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VAMP3 (34). For this reason and because VAMP3 has been found to participate in
secretion in other cell types (60, 61), we began by examining VAMP3 function.
To see if VAMP3 mediates baseline secretion, naïve (uninflamed, nonmetaplastic) WT and VAMP3 KO murine lung sections were stained with PAFS and the
intracellular mucin content was quantified. PAFS stains glycoconjugates red, therefore
heavily glycosylated mucins stain intensely (although this does not distinguish between
mucin types). Typical PAFS image of naïve airways show almost no intracellular mucin
because the rate of mucin secretion matches the rate of constitutive production, as
seen in Fig.7A (top row). However, VAMP3 KO mice show an approximately four-fold
increase in intracellular mucin. This spontaneous accumulation of mucins is indicative
of a baseline secretion defect.
To see if VAMP3 also plays a role in stimulated secretion, mucous metaplasia
was induced in WT and VAMP3 KO mice using an OVA sensitization and challenge
model. The increase in intracellular mucin accumulation between WT and VAMP3 KO
mice was comparable rather than measurably increased in KO mice (Fig. 7A, middle
row), probably because the effect of increased mucin production greatly exceeds the
effect of impaired baseline secretion. When secretion was stimulated with ATP, the
amount of intracellular mucin remaining was similar between WT and KO (Fig. 7A,
bottom row), with fractional mucin release not significantly different between genotypes
(1.90 for WT and 1.90 for KO, P = 0.5077). These findings indicate that VAMP3 KO
mice have no measurable defect in stimulated secretion.
To determine whether VAMP8 is exclusively involved in stimulated secretion,
mirroring the exclusive involvement of VAMP3 in baseline secretion, we examined
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VAMP8 KO mice under naïve conditions. These showed spontaneous accumulation of
mucin (Fig. 7B) to a degree (seven-fold) greater than that in VAMP3 KO mice. This
indicates that both VAMP3 and VAMP8 participate in baseline mucin secretion, with
VAMP8 having a slightly greater role.
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Figure 7. Baseline secretion is mediated by both VAMP3 and VAMP8, but
VAMP3 does not mediate stimulated secretion. Representative images of WT and
KO mouse airway under naïve, metaplastic, and stimulated conditions stained with
PAFS. Intracellular mucin is red. (A)The top row shows naïve airway of WT and
VAMP3 KO mouse airway. Under naïve conditions, VAMP3 WT has a median of 0.35
and VAMP3 KO has a median of 2.20, P = 0.0003, Mann-Whitney test for nonnormal distribution. The second row shows mucous metaplasia induced by OVA.
Under metaplastic conditions, VAMP3 WT has a median of 6.52 and VAMP3 KO has
a median of 6.84, P = 0.4155, Student’s 2-tailed t-test for normal distribution. The
third row shows stimulated secretion of metaplastic airways. VAMP3 WT has a
median of 1.90 and VAMP3 KO has a median of 1.90, P = 0.5077, Student’s 2-tailed
t-test. (B)The naïve airway of WT and VAMP8 KO mouse airway. Under naïve
conditions, VAMP8 WT has a median of 0.47 and VAMP3 KO has a median of 3.28,
P = 0.0002, Student’s 2-tailed t-test. Box shows median and interquartile range and
whiskers show 10th and 90th percentiles. Where significant difference is P < 0.05,
indicated by *. N = 4-5 mice per group. Scale bar is 20 µm.

11.2 VAMP8 KO mouse airways spontaneously accumulate relatively more
Muc5ac than Muc5b
To identify the mucin type spontaneously accumulated, immunofluorescence
staining of Muc5ac and Muc5b was done on naïve WT, VAMP3 KO, and VAMP8 KO
mice. VAMP3 KO and VAMP8 KO mice accumulate both Muc5ac and Muc5b (Fig. 8).
Fluorescence intensity per cell was measured in the airway epithelium of WT, VAMP3
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KO, and VAMP8 KO mice with two mice per group. Compared to WT, VAMP3 KO mice
accumulated approximately two-fold more intracellular Muc5b and two-fold more
Muc5ac. VAMP8 KO mice accumulated three-fold more Muc5b and almost five-fold
more Muc5ac.

Figure 8. VAMP8 KO mice accumulates more Muc5ac spontaneously in the
airway. Representative images of WT, VAMP3 KO and VAMP8 KO mouse airways
stained with antibodies against Muc5ac and Muc5b. Scale bar is 20 µm.

11.3 VAMP3 and VAMP8 both partially colocalize with Muc5ac and Muc5b in
metaplastic airway epithelial cells
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VAMPs are located on the surface of trafficking vesicles in other cell systems
(33), and the functional effects of deletion of VAMP3 and VAMP8 on mucin secretion
suggest these proteins will be found on the surface of mucin granules. As noted in the
Introduction, VAMP2 is the most abundant granule membrane protein in neurons (33).
To visualize whether or not VAMP3 and VAMP8 colocalize with either Muc5ac or
Muc5b or both, we generated highly specific antibodies for each VAMP (Fig. 9). No
granule structures were detected in VAMP3 KO tissue (Fig. 9A) or VAMP8 KO tissue
by the cognate antibodies (Fig. 9B). However, there was some non-specific binding to
the basal bodies of ciliated cells which was identified with an anti-acetylated tubulin
antibody. Granular structures were detected in secretory cells of WT mice with both
antibodies, which yields promise in visualizing the exocytic proteins on mucin granules.
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Figure 9. VAMP3 and VAMP8 antibody staining. (A) WT and VAMP3 KO mouse
airways stained with antibodies against VAMP3, acetylated tubulin (AcTub), and
DAPI. (B) WT and VAMP8 KO mouse airways stained with antibodies against
VAMP8, AcTub, and DAPI. Scale bar is 20 µm.
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In mouse airways treated with IL-13 to induce Muc5ac expression, VAMP3
appears to partially colocalize with Muc5ac and Muc5b (Fig. 10). Some granules
appear to contain only Muc5b (Fig 10B, green arrowhead) and other granules contain
both mucins and VAMP3 (Fig. 10B, white arrow). Colocalization patterns in airway
secretory cells appear to be highly variable (Fig. 10C), in which certain regions and
cells show more colocalization than others. Quantitative colocalization analyses are
underway.
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Figure 10. VAMP3 partially colocalizes with Muc5ac and Muc5b. (A)
Representative image of a mouse airway treated with a high dose of IL-13 and
stained with antibodies against Muc5ac (red) and Muc5b (green) and VAMP3 (blue).
Dashed box indicates region of interest. (B) Single channel view of Muc5ac, Muc5b,
and VAMP3 of secretory cells. Final panel shows all three channels merged. The
green arrowhead indicates lack of colocalization all three markers where the granule
is only Muc5b+. The white arrow indicates colocalization of Muc5ac, Muc5b, and
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VAMP3. (C) Different combinations of only two channels. Colocalization of Muc5ac
and VAMP3 appears as magenta. Colocalization of Muc5b and VAMP3 appears as
cyan, and colocalization of Muc5ac and Muc5b appears as yellow. The green
arrowhead indicates no colocalization and the white arrow indicates colocalization.
Scale bar is 5 µm in A-C.

VAMP8 expression was also examined in metaplastic airway epithelial cells in
conjunction with Muc5ac and Muc5b (Fig. 11). Upon visual inspection, some secretory
cells are either predominantly Muc5ac or Muc5b or they contain both. In secretory cells,
VAMP8 also appears to partially colocalize with Muc5ac and Muc5b. Some granules
contain only Muc5ac and VAMP8 (Fig. 11, red arrowhead) without Muc5b, and some
granules contain Muc5ac, Muc5b, and VAMP8 (Fig. 11, white arrow).
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Figure 11. VAMP8 partially colocalizes with Muc5ac and Muc5b. (A)
Representative image of a mouse airway treated with a high dose of IL-13 and
stained with antibodies against Muc5ac (red) and Muc5b (green) and VAMP8 (blue).
Dashed box indicates region of interest. (B) Single channel view of Muc5ac, Muc5b,
and VAMP8 of a secretory cell. Final panel shows all three channels merged. The
red arrowhead indicates lack of colocalization of all three markers where the granule
is Muc5ac+ and VAMP8+. The white arrow indicates colocalization of Muc5ac,
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Muc5b, and VAMP8. (C) Different combinations of only two channels. Colocalization
of Muc5ac and VAMP8 appears as magenta. Colocalization of Muc5b and VAMP8
appears as cyan, and colocalization of Muc5ac and Muc5b appears as yellow. The
red arrowhead indicates no colocalization of all three markers and the white arrow
indicates colocalization. Scale bar is 5 µm in A-C.

12. Mucin granules are purely in a biosynthetic pathway and do not intersect the
endolysosomal system
In multiple secretory cell types, such as melanocytes, platelets, and mast cells,
the secretory pathway for newly synthesized molecules intersects the endolysosomal
system. This may be indicated by the presence of endolysosomal molecular markers
on secretory granules or the transfer of endocytosed material into nascent secretory
granules. In these cases, the secretory granules may be referred to as lysosomerelated organelles (LROs) (62). It is not yet completely clear whether the presence of
LRO simply reflects the repurposing of trafficking machinery since the exocytosis of
lysosomes appears to be a primitive evolutionary response to calcium to seal defects in
the plasma membrane. However, in some cases there seems to be a physiologic
purpose to including endocytosed material in secretory granules, such as the uptake of
von Willebrand Factor for inclusion in platelet granules to promote thrombosis. Failure
to generate LROs have been linked to genetic diseases such as Hermansky-Pudlak
and Chediak-Higashi syndromes (62).
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Airway epithelial secretory cells have an exocytic machinery closely related to
that of hematopoietic cells including mast cells, as demonstrated by the Dickey/Tuvim
and Adachi laboratories (Syt2, Munc18b, etc), and mast cell secretory granules are
known to intersect the endolysosomal pathway (62). Therefore, to further understand
mucin granule biogenesis, we sought evidence of the presence of endolysosomal
molecular markers on mucin granules, and planned to determine whether endocytosed
macromolecules were trafficked to mucin granules. However, the latter experiments
have not yet been performed due to closure of research laboratories at MD Anderson
because of the coronavirus pandemic. Therefore, only the marker experiments are
presented here and the endocytic experiments will be completed in the future.
The lysosomal associated membrane proteins (LAMPs), LAMP1 and LAMP2, are
the most abundant membrane proteins that reside predominantly on late endosomes
and lysosomes (63). In mouse neurons, LAMP1 has been shown to label a
heterogeneous population of membrane-bound organelles in which some are
lysosome-like, containing hydrolases, and others are endosome-like and
nondegradative (64). To determine if mucin granules intersect with the endolysosomal
pathway, LAMP1 expression was examined in uninflamed (naïve) and inflamed
(metaplastic) airway epithelial cells (Fig. 12). LAMP1 granules were located near the
nucleus and no LAMP1 granules were detected among mucin granules. This suggests
that mucin granules do not intersect the endolysosomal system. No discernable
difference of LAMP1 expression was seen between ciliated and secretory cells in
uninflamed and IL-13 treated mouse airways.
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Figure 12. LAMP1 is not present on mucin granules. Representative images of a
mouse airways stained with antibodies against Muc5ac (red), Muc5b (green), LAMP1
(white) and DAPI (blue). (A) Top row shows a naïve mouse airway. Dashed box
indicates region of interest. Middle row shows single channel view of Muc5ac,
Muc5b, and LAMP1 of a ciliated and secretory cell. Bottom row shows single channel
view of DAPI, merged image of all fluorescent channels, and merged image of all
fluorescent channels and differential interference contrast (DIC). (B) Top row shows
a mouse airway treated with a low dose of IL-13. Dashed box indicates region of
interest. Middle row shows single channel view of Muc5ac, Muc5b, and LAMP1 of a
ciliated and secretory cell. Bottom row shows single channel view of DAPI, merged
image of all fluorescent channels, and merged image of all fluorescent channels and
differential interference contrast (DIC). Scale bar is 5 µm in A-B.
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We also examined LAMP2 localization because it shares a similar distribution
patterns as LAMP1 in late endosomes and lysosomes. LAMP2 has three isoforms,
LAMP2a, LAMP2b, and LAMP2c that have been shown to have different tissue and
subcellular localization patterns. All three isoforms have identical luminal domains but
different transmembrane and cytoplasmic domains (65). The LAMP2 antibody we used
was generated against the luminal region (Fig. 13). Under naïve conditions, LAMP2
was predominantly perinuclear, rarely extending towards the apical mucin-rich region of
secretory cells (Fig. 13A). However under metaplastic conditions, LAMP2 granules
could be seen in the apical region. Nonetheless, Muc5b and LAMP2 appeared to be
spatially separate (Fig. 13B).
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Figure 13. LAMP2 is not present on mucin granules. Representative images of a
mouse airways stained with antibodies against Muc5ac (red), Muc5b (green), LAMP2
(white) and DAPI (blue). (A) Top row shows a naïve mouse airway. Dashed box
indicates region of interest. Middle row shows single channel view of Muc5ac,
Muc5b, and LAMP2 of secretory cells. Bottom row shows single channel view of
DAPI, merged image of all fluorescent channels, and merged image of all fluorescent
channels and differential interference contrast (DIC). (B) Top row shows a mouse
airway treated with a low dose of IL-13. Dashed box indicates region of interest.
Middle row shows single channel view of Muc5ac, Muc5b, and LAMP2 of a secretory
cell. Bottom row shows single channel view of DAPI, merged image of all fluorescent
channels, and merged image of all fluorescent channels and differential interference
contrast (DIC). Scale bar is 5 µm in A-B.

13. Golgi stacks are dispersed in airway secretory cells
To understand the trafficking of mucin granules from their exit from the Golgi
body during biogenesis through to their fusion with the plasma membrane during
exocytosis, I planned to begin by colocalizing mucins with the trans-Golgi-network
marker, TGN46. TGN46, sometimes called TGN38, has been reported to traffic from
the Golgi to the plasma membrane and to return via endosomes (66). In naïve and
metaplastic secretory cells, TGN46 was seen to be distributed in puncta throughout the
entire cell. Under naïve conditions, the secretory cell appeared more compact, with
TGN46 more concentrated among mucin granules (Fig. 14A). In metaplastic
conditions, the secretory cells appeared more elongated and TGN46-positive
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organelles appear more widely spaced apart (Fig. 14B). This is consistent with the
known increase in secretory cell volume during mucous metaplasia (67). Approximately
100 TGN46 positive-organelles were enumerated in secretory cells and there did not
appear to be a significant difference under naïve and metaplastic conditions. In Fig.
14B, next to the secretory cell is a ciliated cell and it can be seen that the number of
TGN46 organelles are far less in number and more perinuclear than in secretory cells.

Figure 14. TGN46 dispersed in secretory cells. Representative images of a mouse
airways stained with antibodies against Muc5ac (red), Muc5b (green), trans-Golginetwork marker TGN46 (white) and DAPI (blue). (A) Top row shows a naïve mouse
airway. Dashed box indicates region of interest. Middle row shows single channel
view of Muc5ac, Muc5b, and TGN46 of a secretory cell. Bottom row shows single
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channel view of DAPI, merged image of all fluorescent channels, and merged image
of all fluorescent channels and differential interference contrast (DIC). (B) Top row
shows a mouse airway treated with a low dose of IL-13. Dashed box indicates region
of interest. Middle row shows single channel view of Muc5ac, Muc5b, and TGN46 of
ciliated and secretory cells. Bottom row shows single channel view of DAPI, merged
image of all fluorescent channels, and merged image of all fluorescent channels and
differential interference contrast (DIC). Scale bar is 5 µm in A-B.

Electron micrographs from the Dickey/Tuvim and Davis laboratories have
previously shown ER and Golgi stacks interspersed among secretory granules (11, 26).
Although the dispersed Golgi phenotype is very different compared to the traditional
view that the Golgi body is consolidated as a single ribbon close to the nucleus in
mammalian cells, gastric parietal cells have also been reported to share this same
phenomenon of dispersed Golgi elements (68). To further characterize the Golgi bodies
in airway epithelial cells, we tested an array of Golgi markers localized to different Golgi
cisternae. GRASP55, a trans-Golgi marker, was also visualized together with Muc5ac
and Muc5b antibodies in naïve and metaplastic mouse airways. In both conditions,
GRASP55 can be seen dispersed within the airway secretory cells and among mucin
granules (Fig. 15).
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Figure 15. GRASP55 dispersed in secretory cells. Representative images of a
mouse airways stained with antibodies against Muc5ac (red), Muc5b (green), transGolgi marker GRASP55 (white) and DAPI (blue). (A) Top row shows a naïve mouse
airway. Dashed box indicates region of interest. Middle row shows single channel
view of Muc5ac, Muc5b, and GRASP55 of secretory cells. Bottom row shows single
channel view of DAPI, merged image of all fluorescent channels, and merged image
of all fluorescent channels and differential interference contrast (DIC). (B) Top row
shows a mouse airway treated with a low dose of IL-13. Dashed box indicates region
of interest. Middle row shows single channel view of Muc5ac, Muc5b, and GRASP55
of ciliated and secretory cells. Bottom row shows single channel view of DAPI,
merged image of all fluorescent channels, and merged image of all fluorescent
channels and differential interference contrast (DIC). Scale bar is 5 µm in A-B.
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To see if the cis-Golgi follows the same trend as the trans-Golgi, thus making a
complete stack, GRASP65, a cis-Golgi marker, was tested in aiway epithelial cells
along with GRASP55 and CCSP, an airway secretory cell marker. Within naïve and
metaplastic mouse airways, both cis- and trans-Golgi markers appear dispersed within
secretory cells identified by CCSP staining (Fig.16).

Figure 16. GRASP65 and GRASP55 are dispersed in secretory cells.
Representative images of a mouse airways stained with antibodies against cis-Golgi
marker GRASP65 (red), trans-Golgi marker GRASP55 (green), club cell secretory
protein CCSP (white) and DAPI (blue). (A) Top row shows a naïve mouse airway.
Dashed box indicates region of interest. Middle row shows single channel view of
GRASP65, GRASP55, and CCSP of a secretory cell. Bottom row shows single
channel view of DAPI, merged image of all fluorescent channels, and merged image
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of all fluorescent channels and differential interference contrast (DIC). (B) Top row
shows a mouse airway treated with a low dose of IL-13. Dashed box indicates region
of interest. Middle row shows single channel view of GRASP65, GRASP55, and
CCSP of a secretory cell. Bottom row shows single channel view of DAPI, merged
image of all fluorescent channels, and merged image of all fluorescent channels and
differential interference contrast (DIC). Scale bar is 5 µm in A-B.
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Discussion
Our laboratory has studied airway mucin secretion for two decades because of
its pathobiological significance and its cell biological interest as a model of regulated
secretion. Just before I joined the laboratory, the discovery had been made that two
distinct plasma membrane exocytic machines mediate baseline and stimulated mucin
secretion(36). Since two mucins, MUC5AC and MUC5B, are synthesized and secreted
in the airway, an obvious question was whether they utilize distinct secretory pathways
ending in the two plasma membrane exocytic machines. My work began by addressing
whether these two mucins are packaged into the same or different granules, and
whether distinct granule exocytic proteins mediate secretion of each mucin. In pursuing
these questions, this work led to more fundamental questions about mucin granule
biogenesis including whether the biosynthetic pathway intersects the endolysosomal
system, and how the Golgi system organizes assembly of mucin cargo with granule
exocytic components.
I begin my work by analyzing the colocalization of Muc5ac and Muc5b to
determine whether or not they are packaged in the same or separate granules. Within
the same airway, not all secretory cells have the same expression level of Muc5ac and
Muc5b, as some cells express only Muc5b, some cells express only Muc5ac, and some
cells express both mucins. We analyzed only cells that express both mucins, but even
that population is highly variable in terms of expression levels. Within a secretory cell
that contains both mucins, there are three types of granules; Muc5ac only, Muc5b only,
and granules containing both Muc5ac and Muc5b. Thus, Muc5ac and Muc5b are
partially colocalized in mice and human airways, but the mechanism and signals
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controlling their packaging are not yet understood. A manuscript reporting a more
thorough analysis of Muc5ac and Muc5b colocalization patterns in cells and tissues of
mice and humans is in progress.
Next, I examined VAMP3 and VAMP8 as potential components of the granulelocalized exocytic machinery and as membrane markers for mucin granules. VAMP8
has been reported to mediate stimulated secretion; however, the VAMP(s) mediating
baseline secretion had yet to be identified (34). I found that both VAMP3 and VAMP8
mediate baseline secretion of mucins, and that both VAMPs partially colocalize with
both mucins using isoform-specific antibodies raised in chickens. Although deletion of
either VAMP result in spontaneous accumulation of mucin in secretory cells, indicating
a defect in baseline secretion, VAMP8 deficiency had a greater defect than VAMP3
deficiency. A second manuscript is planned for a more thorough examination of the
roles of VAMP3 and VAMP8 in airway mucin secretion and the localization of Muc5ac
and Muc5b within these granules. In addition, I have been breeding airway-specific
VAMP8 conditional deletant mice future experiments to determine if VAMP8 deletion
would provide protection in disease models where mucus hypersecretion is
pathological. We hypothesize that that these mice will be healthy because VAMP3
might be able to maintain a sufficient level of baseline mucin secretion to sustain
homeostatic airway clearance. We further hypothesize that the only significant defense
defect in these mice will be in trapping helminths migrating through the lungs, and have
established collaboration with a group in Manchester, England that has set up such as
mouse model (18). VAMP3 KO and VAMP8 deletant mice are also being bred together
to determine if deletion of both VAMPs will completely ablate mucin secretion. Those
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mice are being used for breeding since VAMP3/8 double KO mice are embryonically
lethal (60). Last, VAMP3 and VAMP8 are being conjugated to the APEX peroxidase for
electron microscopy and to perform proximity proteomic analyses of VAMP-specific
granules(69, 70).
In the process of analyzing mucin packaging within granules, it is vital that the
nature of the mucin granule be examined as well. Not all secreted proteins travel in a
linear fashion from ER-to-Golgi-to plasma membrane. Some cells that specialize in
secretion, such as melanocytes, platelets, and lung alveolar type 2 epithelial cells all
have lysosome-related organelles (LROs) in which endocytosed material is mixed with
biosynthetic material exiting the Golgi. LROs are different from lysosomes in that the
contents are destined for secretion rather than degradation. LAMP1 and LAMP2 were
examined in airway epithelial cells and there appeared to be no intersection of the
endolysosomal system with mucin granules. However, these results are not definitive in
defining LROs and further experiments are required for confirmation. These include
determining whether or not endocytosed material such as fluorescent-labelled dextran
can be incorporated into mucin granules, and the examination of endosomal markers
such as Rab7 and CD63. These studies have been planned for the spring, but could
not be performed due the pandemic quarantine. They are now underway.
Another aspect in studying mucin granule biogenesis involves determining when
and where the exocytic machinery, including VAMPs, associates with a mucin granule.
Seven different Golgi markers were tested and it was determined that the cis-Golgi
marker GRASP65, the trans-Golgi marker GRASP55, and the trans-Golgi network
marker TGN46 all have dispersed staining patterns within airway secretory cells. In
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contrast to the classic Golgi structure of mammalian cells organized into a smaller
number of stacks linked together in a ribbon structure adjacent to the nucleus (71),
airway secretory cells were found to contain >100 widely dispersed Golgi stacks.
The number of Golgi stacks did not differ significantly between uninflamed and inflamed
airway secretory cells despite the marked increase in mucin production. It was
interesting that mucins did not clearly appear to associate with the TGN. However, this
could be due to mucins being rapidly sent to storage granules as soon as they are
processed in the Golgi, and that light microscopy is not sensitive enough to capture
that. Future studies of the Golgi in airway secretory cells will require higher resolution
techniques such as electron microscopy. A third manuscript is planned characterizing
mucin granule biogenesis, and this would incorporate data obtained from experiments
examining exit from the Golgi and the intersection with the endolysosomal system.
Understanding mucin granule biogenesis has important implications for lung cell
biology and common lung diseases in which mucus is pathological. Asthma, CF,
COPD, and IPF are all lung disease in which mucin trafficking plays an important role in
pathogenesis. What is learned from mucin granule biogenesis could impact future
treatment options available for those diseases.
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Methods
Mice
For WT mice, 6-week old female C57BL/6J mice were purchased from the
Jackson Laboratory (Bar Harbor, ME) and entered into protocols from 1 to 4 weeks
after arrival. We have found no difference in mucous metaplasia or secretion efficiency
between female and male mice from ages 6 to 26 weeks. Mice were housed up to 5
per cage in individually ventilated cages in a specific pathogen-free facility where the
exposure to dust was minimized by quarter-inch corn cobb bedding, in controlled
temperature (21 °C), relative humidity (55%) and a 12-hour light/dark cycle. Standard
chow and water were available ad libitum. The animal care and experimental protocols
were approved by the Institutional Animal Care and Use Committee (permit number
00001214-RN02).
Mice aged 8 - 21 weeks of both sexes were used for VAMP KO experiments.
VAMP8 KO mice were obtained from Herbert Y. Gaisano (Departments of Medicine
and Physiology, University of Toronto, Ontario, Canada) with permission from Wanjin
Hong (Institute of Molecular and Cellular Biology, National University of Singapore,
Singapore) and maintained on a mixed background of 129 SvJ and C57BL/6. VAMP3
KO mice were obtained from Jeffrey E. Pessin (Department of Physiology and
Biophysics, The University of Iowa, Iowa, USA) and maintained on a C57BL/6
background.
Before sacrifice, all mice were anesthetized with tribromoethanol (MilliporeSigma
T48402) intraperitoneally and exsanguinated by severing the abdominal aorta. The
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right cardiac ventricle was perfused with PBS to clear blood from lung tissue. Lungs
were inflated at 20 cmH2O and fixed with 4% paraformaldehyde in PBS overnight at 4
°C. The left lobe was cut to expose the axial bronchus. After processing, the sample
was embedded in paraffin and cut into 5 µm thick sections.
Induction of mucous metaplasia
For study of intracellular accumulation of mucin, mucous metaplasia was
induced using an ovalbumin sensitization model. Mice were sensitized by
intraperitoneal injections (20 µg OVA grade V, 2.25 mg alum in 100 µL 0.9% saline
MilliporeSigma) once a week for three weeks. Sensitized mice were then exposed to a
20 minute aerosol challenge of 2.5% (wt/vol) OVA in 0.9% saline with 0.02% antifoam
A silicon polymer (Sigma-Aldrich A5633-100G) daily for 5 days via an AeroTech II
nebulizer (Biodex) driven by 10 L/min of a mixture of 95% room air supplemented with
5% CO2 to induce deep ventilation. Three days after the last aerosol challenge, half of
the mice were harvested and half were exposed to an aerosol of 100 mM ATP
(MilliporeSigma) in 0.9% saline to stimulate secretion for 10 minutes prior sacrifice.
For studies of mucin colocalization, VAMPs, LAMPs, and Golgi bodies, mucous
metaplasia in mice was induced using either IL-13 (BioLegend #575908) or IL-1β
(BioLegend #575108) given intrapharyngeally while anesthetized with isoflurane. A low
dose treatment was one instillation of 1 µg of either cytokine in 40 µL of 0.1 M
phosphate buffered saline (pH 7.4) with harvest two days later. A high dose treatment
was one instillation of 2 µg in 40 µL of PBS daily for three days with harvest two days
after the last instillation.
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Human tissue
For systematic examination of proximal human airways, de-identified tissue was
obtained at the University of Texas Health Science Center under an approved
institutional review board protocol (HSC-MS-08-0354/HSC-MS-15-1049). Lobar
bronchial tissue from lungs donated but not used for transplantation was dissected free
from major vessels and pleural tissue. A 1-1.5 cm longitudinal piece of bronchus near
the midpoint between its take-off from the mainstem bronchus and its termination at
segmental bronchi branching was excised and placed in 10% neutral buffered formalin
for 24 hours at 4 ºC overnight, then embedded in paraffin.
For systematic examination of distal human airways, precision-cut lung slices
were prepared at Rutgers University from de-identified tissue not requiring institutional
review board approval, as described (72, 73). Briefly, one lobe from a donated healthy
human lung was isolated by dissection and inflated through the bronchus using 2%
(wt/vol) low melting point agarose at room temperature. The temperature was then
lowered to 7 ºC, and when the agarose set, the lobe was sectioned perpendicular to
major airways. Next, using a dissecting microsope, cylindrical cores 12 mm long and 8
mm in diameter were taken around visible airways, then sliced at a thickness of 350 μm
(Precisionary Instruments VF300 Vibratome, Greenville, NC). Slices were placed in
wells containing supplemented Ham’s F-12 medium for 24 hours, with the medium
changed three times. After 24 hours, slices containing a small airway (<1 mm diameter)
with beating cilia under microscopic inspection were fixed with PFA during overnight
shipment to MD Anderson Cancer Center, then switched to PBS overnight before
embedding in paraffin.
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Colocalization analysis of Muc5ac and Muc5b
Z-stacked images of 0.5 µm steps were taken on a widefield deconvolution
microscope (DeltaVision Elite, GE Healthcare, USA) using a 100x lens (UPLSAPO
100XO 1-U2B836, NA 1.4, Olympus, Japan) and 0.23 m optical sections. Images
were then deconvolved with Softworx software (GE Healthcare, USA).The plugin
JACoP was used in an open source image processing software, Fiji, for colocalization
analysis (74). Each region of interest analyzed was a Z-stack of a single cell. The
threshold used in the plugin is the default in which threshold = (average background +
average objects)/2. Briefly, Z-stack of a single cell was split into single color channels.
Two channels were selected for colocalization analysis and assigned either “Image A”
or “Image B”. Options for Pearson’s coefficient and M1 & M2 Mander’s coefficients
were selected and the values generated were plotted. Line plot analysis was performed
on background-corrected images. A line that measured the greatest length of a single
cell in a single XY-plane image was drawn, and fluorescence intensities along the line
were plotted.
Airway epithelial mucin content by PAFS staining and image analysis
Mouse tissue sections were stained with periodic acid fluorescent Schiff (PAFS)
reagent to label mucins fluorescent red. UV images were taken on an Olympus BX60
upright microscope using a 40x NA 0.75 objective lens. The entire circumference of the
axial bronchus was imaged, and intracellular mucin was measured as the red pixel
area using ImagePro (Media Cybernetics). Data was presented as mucin volume over
the surface area of the basement membrane (11).
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Statistics
Statistical analyses were performed using GraphPad Prism, with P < 0.05
considered significant. Exact P values and n values for each sample are included in the
figure legend. Statistical analysis was performed using Student’s 2-tailed t test or
Mann-Whitney U test after determining normality of the data using Shapiro-Wilk test.
For box plots, box shows median and interquartile range and whiskers show 10th and
90th percentiles.
Immunofluorescence
Deparaffinized lung sections were placed in a 10 mM sodium citrate (pH 6.0)
bath and heated in a pressure cooker for 10 minutes. After being cooled, sections were
washed with PBS and permeabilized with 0.3% Triton X-100 in PBS for 20 minutes.
Then, sections were blocked with 5% normal donkey serum (Jackson
ImmunoResearch) in PBS and 0.05% Tween 20 for 1 hour. Primary antibodies (Table 1
and Table 2) were diluted with the same blocking solution and incubated overnight at 4
°C. The following day, sections were washed and incubated with secondary antibodies
(Table 3) diluted in PBST for 1 hour. Vector TrueVIEW Autofluorescence Quenching Kit
(SP-8400) was used prior to mounting. Slides were left to cure in the dark at room
temperature overnight prior to long term storage at 4 °C. Z-stacked images of 0.5 μm
steps were taken on a confocal microscope (Nikon A1, Japan) using a 60x lens
(Apochromat TIRF 60XO, NA 1.49, Nikon, Japan). Settings were optimized using the
Nyquist rate.
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To determine fluorescence intensity per cell, images were taken on an Olympus
BX60 upright microscope using a 40x NA 0.75 objective lens at the same exposure
settings. Total fluorescence for Muc5ac and Muc5b was measured in the airway
epithelium using the software Fiji and divided by the number of cells, indicated by
DAPI.
Primary antibodies for airway epithelial cells and mucins
Name
Anti-Tubulin, Acetylated

Location
Cilia

CCSP (Clara/ club cell
secretory protein)/ Unteroglobin
Muc5ac (45M1)

Airway
secretory cells
Airway
secretory cells
Airway
secretory cells

Muc5ac (UNC294)

Muc5b (3E1)

Airway
secretory cells

Muc5b (UNC222)

Airway
secretory cells

Muc5b (OAEB02744)

Airway
secretory cells

VAMP3 (Vesicle Associated
Membrane Protein 3)
VAMP8 (Vesicle Associated
Membrane Protein 8)

Vesicle
Vesicle

Concentration Vendor
1:1000
Sigma-Aldrich T6793
Mouse Monoclonal
1:1000
EMD Millipore ABS1673
Goat Polyclonal
1:500
Invitrogen MA5-12178
Mouse Monoclonal
1:500
University of North
Carolina UNC294
Rabbit Polyclonal
1:1000
Millipore Sigma
MABT899
Mouse Monoclonal
1:1000
University of North
Carolina UNC222
Rabbit Polyclonal
1:1000
Aviva Systems Biology
OAEB02744
Goat Polyclonal
1:100
Texas A&M
Chicken Polyclonal
1:500
Texas A&M
Chicken Polyclonal

Table 1. Primary antibodies for airway epithelial cells and mucins.

Primary antibodies for Golgi and lysosomes
Name
58K

Location
Golgi

Alexa Fluor® 555 Mouse antiGM130
Golgin45/
BLZF1 (basic leucine zipper
nuclear factor 1)

cis-Golgi

Concentration Vendor
1:100
Abcam ab19072
Goat Polyclonal
1:100
BD Biosciences 560066
Mouse Monoclonal
1:100
Aviva Systems Biology
OAAN01805
Rabbit Polyclonal

cis-Golgi,
nucleus
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Golgin97

trans-Golgi

1:100

GRASP55 (Golgi Reassembly
Stacking Protein of 55kDa)

medial/
trans-Golgi

1:100

GRASP65 (Golgi Reassembly
Stacking Protein of 65kDa)

cis-Golgi

1:100

TGN46

trans-Golgi
network
Late
endosome,
lysosome
Late
endosome,
lysosome
Late
endosome,
lysosome

1:100

LAMP1 (Lysosomal
Associated Membrane Protein
1) / CD107a
LAMP2 (Lysosomal
Associated Membrane Protein
2)/ CD107b
LAMP3 (Lysosomal
Associated Membrane Protein
3)/ CD208

1:500

1:500

1:500

Cell Signaling Technology
13192
Rabbit Monoclonal
Novus Biologicals NBP189747
Rabbit Polyclonal
Santa Cruz Biotechnology
sc-374423
Mouse Monoclonal
Abcam ab165059
Rabbit Polyclonal
Developmental Studies
Hybridoma Bank 1D4B
Rat Monoclonal
Developmental Studies
Hybridoma Bank GL2A7
Rat Monoclonal
Synaptic Systems 391005
Guinea Pig Polyclonal

Table 2. Primary antibodies for Golgi and lysosomes.

Secondary antibodies
Name
Donkey anti-Mouse IgG (H+L) Highly CrossAdsorbed Secondary Antibody, Alexa Fluor 488
Donkey anti-Mouse IgG (H+L) Highly CrossAdsorbed Secondary Antibody, Alexa Fluor 555
Alexa Fluor® 488 AffiniPure Donkey Anti-Rabbit
IgG (H+L)
Cy™3 AffiniPure Donkey Anti-Rabbit IgG (H+L)

Alexa Fluor® 647 AffiniPure Donkey Anti-Rabbit
IgG (H+L)
Alexa Fluor® 488 AffiniPure Donkey Anti-Rat IgG
(H+L)
Alexa Fluor® 488 AffiniPure Donkey Anti-Guinea
Pig IgG (H+L)
Alexa Fluor® 488 AffiniPure Donkey AntiChicken IgY (IgG) (H+L)

Table 3. Secondary antibodies.
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Concentration Vendor
1:1000
ThermoFisher Scientific
A-21202
1:1000
ThermoFisher Scientific
A-31570
1:1000
Jackson
ImmunoResearch
715-545-152
1:1000
Jackson
ImmunoResearch
711-165-152
1:1000
Jackson
ImmunoResearch
711-605-152
1:1000
Jackson
ImmunoResearch
712-545-153
1:1000
Jackson
ImmunoResearch
706-545-148
1:1000
Jackson
ImmunoResearch
703-545-155

Generation of VAMP antibodies
Specific antibodies against murine VAMP3 and VAMP8 were generated in
chickens using peptides specific for each isoform. Briefly, peptides were conjugated to
an immune complex targeting chicken CD40 to enhance an immune response at Texas
A&M (75). Chickens were immunized subcutaneously in the wing web with 50µg of
petide complex and boosted four times prior to a terminal bleed. Peptide sequence
GVPSGSSAATGC was used for VAMP3 and DRVRNLQSEVEGC for VAMP8.
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